Table 5. Patient characteristics according to molecular subtype.
| EBV (n=7) | MSI (n=19) | CIN (n=46) | GS (n=35) | P value | |||||
|---|---|---|---|---|---|---|---|---|---|
| Cases | (%) | Cases | (%) | Cases | (%) | Cases | (%) | ||
| Age | |||||||||
| ≤50 | 0 | 0.0% | 1 | 5.3% | 3 | 6.5% | 6 | 17.1% | 0.580 |
| 51 ∼60 | 2 | 28.6% | 1 | 5.3% | 9 | 19.6% | 6 | 17.1% | |
| 61 ∼70 | 1 | 14.3% | 3 | 15.8% | 13 | 28.3% | 8 | 22.9% | |
| 71 ∼ 80 | 3 | 42.9% | 12 | 63.2% | 16 | 34.8% | 13 | 37.1% | |
| >80 | 1 | 14.3% | 2 | 10.5% | 5 | 10.9% | 2 | 5.7% | |
| Sex | |||||||||
| Female | 1 | 14.3% | 8 | 42.1% | 16 | 34.8% | 11 | 31.4% | 0.660 |
| Male | 6 | 85.7% | 11 | 57.9% | 30 | 65.2% | 24 | 68.6% | |
| Lauren Class | |||||||||
| Diffuse | 3 | 42.9% | 2 | 10.5% | 9 | 19.6% | 14 | 40.0% | 0.069 |
| Intestinal | 2 | 28.6% | 15 | 78.9% | 26 | 56.5% | 15 | 42.9% | |
| Mixed | 2 | 28.6% | 2 | 10.5% | 11 | 23.9% | 6 | 17.1% | |
| WHO Class | |||||||||
| Tubular | 2 | 28.6% | 17 | 89.5% | 32 | 69.6% | 18 | 51.4% | 0.000 |
| Mucinous | 0 | 0.0% | 0 | 0.0% | 2 | 4.3% | 1 | 2.9% | |
| Poorly cohesive | 0 | 0.0% | 0 | 0.0% | 5 | 10.9% | 9 | 25.7% | |
| Mixed | 1 | 14.3% | 1 | 5.3% | 7 | 15.2% | 7 | 20.0% | |
| Uncommon | 4 | 57.1% | 1 | 5.3% | 0 | 0.0% | 0 | 0.0% | |
| pT stages | |||||||||
| T1a/ T1b | 2 | 28.6% | 2 | 10.5% | 10 | 21.7% | 10 | 28.6% | 0.778 |
| T2 | 1 | 14.3% | 3 | 15.8% | 4 | 8.7% | 3 | 8.6% | |
| T3 | 1 | 14.3% | 9 | 47.4% | 17 | 37.0% | 11 | 31.4% | |
| T4a/ T4b | 3 | 42.9% | 5 | 26.3% | 15 | 32.6% | 11 | 31.4% | |
| p N stages | |||||||||
| N0 | 3 | 42.9% | 10 | 52.6% | 16 | 34.8% | 11 | 31.4% | 0.802 |
| N1 | 1 | 14.3% | 3 | 15.8% | 7 | 15.2% | 5 | 14.3% | |
| N2 | 1 | 14.3% | 4 | 21.1% | 9 | 19.6% | 6 | 17.1% | |
| N3 | 2 | 28.6% | 2 | 10.5% | 14 | 30.4% | 13 | 37.1% | |
| M stages | |||||||||
| M0 | 6 | 85.7% | 19 | 100.0% | 43 | 93.5% | 34 | 97.1% | 0.351 |
| M1 | 1 | 14.3% | 0 | 0.0% | 3 | 6.5% | 1 | 2.9% | |
| AJCC Stages | |||||||||
| Stages IA/IB | 3 | 42.9% | 4 | 21.1% | 11 | 23.9% | 11 | 31.4% | 0.605 |
| Stages IIA/IIB | 1 | 14.3% | 9 | 47.4% | 13 | 28.3% | 3 | 8.6% | |
| Stages IIIA/IIIB/IIIC | 2 | 28.6% | 6 | 31.6% | 19 | 41.3% | 20 | 57.1% | |
| Stage IV | 1 | 14.3% | 0 | 0.0% | 3 | 6.5% | 1 | 2.9% | |
| Anatomical regions | |||||||||
| Antrum | 1 | 14.3% | 15 | 78.9% | 25 | 54.3% | 13 | 37.1% | 0.004 |
| Antrum_Body | 1 | 14.3% | 0 | 0.0% | 2 | 4.3% | 2 | 5.7% | |
| Fundus_Body | 4 | 57.1% | 4 | 21.1% | 10 | 21.7% | 18 | 51.4% | |
| GEJ_Cardia | 1 | 14.3% | 0 | 0.0% | 7 | 15.2% | 0 | 0.0% | |
| Diffuse | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.9% | |
| Pylorus | 0 | 0.0% | 0 | 0.0% | 2 | 4.3% | 1 | 2.9% | |
| Lymphatic invasion | |||||||||
| Positive | 4 | 57.1% | 17 | 89.5% | 34 | 73.9% | 21 | 60.0% | 0.125 |
| Negative | 3 | 42.9% | 2 | 10.5% | 12 | 26.1% | 13 | 37.1% | |
| Missing | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.9% | |
| Venous invasion | |||||||||
| Positive | 2 | 28.6% | 1 | 5.3% | 7 | 15.2% | 5 | 14.3% | 0.416 |
| Negative | 5 | 71.4% | 18 | 94.7% | 39 | 84.8% | 29 | 82.9% | |
| Missing | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.9% | |
| Perineural invasion | |||||||||
| Positive | 4 | 57.1% | 6 | 31.6% | 25 | 54.3% | 17 | 48.6% | 0.391 |
| Negative | 3 | 42.9% | 13 | 68.4% | 21 | 45.7% | 17 | 48.6% | |
| Missing | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.9% | |
| H. pylori infection | |||||||||
| Negative | 3 | 42.9% | 8 | 42.1% | 21 | 45.7% | 9 | 25.7% | 0.290 |
| Positive | 4 | 57.1% | 11 | 57.9% | 25 | 54.3% | 26 | 74.3% | |
Abbreviations: CIN, chromosomal instability, EBV, Epstein-Barr virus; GS, genomically stable; gastric cancer, GC; GEJ, gastroesophageal junction; H. pylori, Helicobacter pylori; MSI, microsatellite instability; Mixed, mixed type with tubular and poorly cohesive; pT stage, pathological assessment of the primary tumor; pN stage, pathological assessment of the regional lymph nodes; Uncommon, uncommon histologic variants.